Journal of Neuro-Oncology
© Springer Science+Business Media B.V. 2007
10.1007/s11060-012-1002-5

RETRACTED ARTICLE: A single chain (scFv425):sTRAIL fusion protein with specificity for the EGF receptor is effective in vitro but not in an in vivo brain tumor animal model

Jos M. A. Kuijlen , Jan Jakob A. Mooij1, Wijnand Helfrich2 and Wilfred F. A. den Dunnen3
(1)
Department of Neurosurgery, University Medical Center Groningen, University Hospital Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
(2)
Department of Pathology and Laboratory Medicine, Section Medical Biology, Laboratory for Tumor Immunology, University Medical Center Groningen, University Hospital Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
(3)
Department of Pathology and Laboratory Medicine, University Medical Center Groningen, University Hospital Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, The Netherlands
 
 
Jos M. A. Kuijlen
Received: 31 October 2006Accepted: 15 December 2006Published online: 7 May 2008
Without Abstract
The article has been retracted by agreement between the authors and the editors. The reasons for retraction are specified in the retraction statement that replaces the original publication.

Retraction statement

The article has been retracted by agreement between the authors and the editors. The reasons for retraction are twofold:
1
First author Mr Kuijlen failed to inform Dr. Helfrich on the contents of the manuscript, on the fact it was submitted for publication, and that Dr. Helfrich was listed as an author.
 
2
Only after online publication Dr. Helfrich became aware of this work in which he immediately detected mistakes in Mr Kuijlen’s assumptions and calculations.
 
All listed authors agree on the fact that the conclusion (also given in the title) about inactivity of the scFv425:sTRAIL fusion protein in vivo is unjustified. Therefore this publication should be ignored. Mr Kuijlen apologizes to all authors and to the editors and readership of the Journal of Neurooncology.